Virginia Paton

18.2k total citations · 3 hit papers
31 papers, 13.3k citations indexed

About

Virginia Paton is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Virginia Paton has authored 31 papers receiving a total of 13.3k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Virginia Paton's work include HER2/EGFR in Cancer Research (14 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Peptidase Inhibition and Analysis (6 papers). Virginia Paton is often cited by papers focused on HER2/EGFR in Cancer Research (14 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Peptidase Inhibition and Analysis (6 papers). Virginia Paton collaborates with scholars based in United States, Australia and Canada. Virginia Paton's co-authors include Steven Shak, Dennis J. Slamon, Janet Wolter, Alex Bajamonde, José Baselga, Mark D. Pegram, Thomas Fleming, W. Eiermann, Brian Leyland‐Jones and Larry Norton and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Annals of Internal Medicine.

In The Last Decade

Virginia Paton

30 papers receiving 13.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

2001 8.4k citations Dennis J. Slamon, Brian Leyland‐Jones et al. New England Journal of Medicine profile →
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

1999 2.2k citations Melody Cobleigh, Charles L. Vogel et al. Journal of Clinical Oncology profile →
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience

2002 1.1k citations Andrew D. Seidman, Clifford A. Hudis et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Virginia Paton

Since Specialization

Citations

This map shows the geographic impact of Virginia Paton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Virginia Paton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Virginia Paton more than expected).

Fields of papers citing papers by Virginia Paton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Virginia Paton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Virginia Paton. The network helps show where Virginia Paton may publish in the future.

Co-authorship network of co-authors of Virginia Paton

This figure shows the co-authorship network connecting the top 25 collaborators of Virginia Paton. A scholar is included among the top collaborators of Virginia Paton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Virginia Paton. Virginia Paton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	127TiP Phase II, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine (CX 2009) in metastatic HR-positive/HER2 non-amplified breast cancer (mHR+/HER2− BC) and CX-2009 as monotherapy and in combination with pacmilimab in metastatic triple-negative breast cancer (mTNBC) 2021 ·Annals of Oncology ·Kathy D. Miller, Leisha A. Emens, Sara M. Tolaney, Sara A. Hurvitz, Erika Hamilton, Virginia Paton, Alison L. Hannah, Valentina Boni	0
2	Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial 2019 ·The Lancet Oncology ·Michael Friedländer, Tarek Meniawy, Ben Markman, Linda Mileshkin, Paul R. Harnett, Michael Millward, Joanne Lundy, Alison Freimund, (unknown), Song Mu, John Wu, Virginia Paton, Bo Gao	89
3	Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung 2017 ·Journal of Clinical Oncology ·David R. Spigel, Martin J. Edelman, Kenneth J. O’Byrne, Luis Paz‐Ares, Simonetta Mocci, See Phan, David S. Shames, Dustin Smith, Wei Yu, Virginia Paton, Tony Mok	232
4	Dose escalation/expansion study to investigate the safety, pharmacokinetics, food effect, and antitumor activity of BGB-290 in patients with advanced solid tumors 2017 ·Annals of Oncology ·Jason D. Lickliter, Linda Mileshkin, Mark Voskoboynik, Michael Millward, Alison Freimund, Tarek Meniawy, (unknown), (unknown), (unknown), Virginia Paton	6
5	A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors. 2017 ·Journal of Clinical Oncology ·Michael Friedländer, Tarek Meniawy, Ben Markman, Linda Mileshkin, Paul R. Harnett, Michael Millward, Joanne Lundy, Alison Freimund, (unknown), Song Mu, John Z. Wu, Virginia Paton, Lai Wang, Bo Gao	25
6	Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program 2015 ·PLoS ONE ·Roland Morley, (unknown), Peter G. Hawkins, Y. Suzuki, Virginia Paton, See‐Chun Phan, Mark Merchant, Jessie J. Hsu, Wei Yu, Qi Xia, Daniel O. Koralek, Patricia Luhn, (unknown)	18
7	Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma 2012 ·Cancer ·Darrell White, Adetola A. Kassim, (unknown), Jing Yi, (unknown), Virginia Paton	57
8	Independent Adjudication of Symptomatic Heart Failure With the Use of Doxorubicin and Cyclophosphamide Followed by Trastuzumab Adjuvant Therapy: A Combined Review of Cardiac Data From the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 Clinical Trials 2010 ·Journal of Clinical Oncology ·Stuart D. Russell, Kimberly Blackwell, Julia Lawrence, John Pippen, Matthew T. Roe, (unknown), Virginia Paton, Eric Holmgren, Kenneth W. Mahaffey	149
9	Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer 2009 ·Journal of Clinical Oncology ·Sharmila Makhija, Lukas C. Amler, (unknown), Frederick R. Ueland, Michael A. Gold, Don S. Dizon, Virginia Paton, Chin‐Yu Lin, Thomas Januario, Kimmie Ng, Andreas C. Strauß, Stephen M. Kelsey, Mark X. Sliwkowski, Ursula A. Matulonis	132
10	Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum-resistant disease 2008 ·Journal of Clinical Oncology ·Deepa Lalla, Virginia Paton, Chin‐Yu Lin, Don S. Dizon	2
11	Cost‐effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2‐positive breast cancer 2007 ·Cancer ·Louis P. Garrison, Deborah P. Lubeck, Deepa Lalla, Virginia Paton, Amylou C. Dueck, Edith A. Perez	96
12	Hormone Receptor Status Does Not Affect the Clinical Benefit of Trastuzumab Therapy for Patients with Metastatic Breast Cancer 2005 ·Clinical Breast Cancer ·Adam Brufsky, Barry C. Lembersky, Kathy Schiffman, Grazyna Liebérman, Virginia Paton	43
13	Effect of Cardiac Dysfunction on Treatment Outcomes in Women Receiving Trastuzumab for HER2-Overexpressing Metastatic Breast Cancer 2004 ·Clinical Breast Cancer ·Debu Tripathy, Andrew D. Seidman, Deborah Keefe, Clifford A. Hudis, Virginia Paton, Grazyna Liebérman	26
14	Reporting of adverse event data in hematopoietic stem cell transplantation clinical trials involving investigational new drugs or devices: A report from the William Guy Forbeck Foundation 2001 focus meeting on clinical trials in hematopoietic stem cell transplantation 2002 ·Biology of Blood and Marrow Transplantation ·Paul J. Martin, Joseph H. Antin, Daniel J. Weisdorf, Virginia Paton, Mary M. Horowitz	7
15	Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 breakdown → 2001 ·New England Journal of Medicine ·Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak, (unknown), Virginia Paton, Alex Bajamonde, Thomas Fleming, W. Eiermann, Janet Wolter, Mark D. Pegram, José Baselga, Larry Norton	8436
16	Placebo‐associated remissions in a multicentre, randomized, double‐blind trial of interferon γ‐1b for the treatment of metastatic renal cell carcinoma 2000 ·British Journal of Urology ·M. Elhilali, M.E. Gleave, Yves Fradet, Ian D. Davis, Peter Venner, Fred Saad, Laurence Klotz, Ronald B. Moore, Scott Ernst, Virginia Paton, (unknown)	39
17	Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease breakdown → 1999 ·Journal of Clinical Oncology ·Melody Cobleigh, Charles L. Vogel, Debu Tripathy, Nicholas J. Robert, Suzy Scholl, Louis Fehrenbacher, Janet Wolter, Virginia Paton, Steven Shak, (unknown), Dennis J. Slamon	2174
18	Interferon Gamma-1b Compared With Placebo in Metastatic Renal-Cell Carcinoma 1999 ·The Journal of Urology ·M.E. Gleave, M. Elhilali, Yves Fradet, Ian D. Davis, Peter Venner, Fred Saad, (unknown), Malcolm J. Moore, Virginia Paton, Alex Bajamonde	12
19	Interferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell Carcinoma 1998 ·New England Journal of Medicine ·Martin Gleave, Mostafa Elhilali, Yves Fradet, Ian D. Davis, Peter Venner, Fred Saad, Laurence Klotz, Malcolm J. Moore, Virginia Paton, Alex Bajamonde, David Bell, Scott Ernst, Ernest W. Ramsey, Joe Chin, Álvaro Morales, (unknown), C. Sanders	217
20	The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon. 1998 ·PubMed ·Eric J. Small, Geoffrey R. Weiss, (unknown), Philip Walther, Deborah G. Johnson, (unknown), Timothy M. Kuzel, Alex Bajamonde, Virginia Paton	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact